Since 2014 we offer Service and Consulting for Clinical Development                                       

We GUIDE you from bench to bedside – Our mission is to be a flexible and smart provider of support, service and consulting for clinical development of therapeutics especially for small biotech, start-up projects and investigator sponsored trials.


We will support you through all aspects of early development to large clinical trials. Along this way we can be your GUIDE, but we can also be your SHERPA carrying part of your load - Anyhow, we will be good company.


We support you to select the right partners, investigators and CROs according to GCP.


We help you to bring your drug in suitable animal models and translate your research results into doable study protocols giving you meaningful results in the end.


We develop, improve or challenge your quality management system to meet your organization's needs and authorities' expectations, helping you to survive inspections and due diligences.


Irrespective if you are an academic investigator or a financial investor  - we evaluate your needs and offer you solutions and guidance along your path –always focused on your specific exit - no matter if this is the publication in a prestigious journal, the partnering with a big pharma company or the market authorization of your drug.


Meet GUIDED Development


6. - 8. November 2023 in Munich

BIO-Europe 2023

                  24. Nov 2023 in München

                  31. BVMA Symposium


GUIDED Publications

We are proud to be part of the follwing scientific publications



Blank A, Hohmann N, Dettmer M, Manka-Stuhlik A, Mikus G, Stoll F, Stützle-Schnetz M, Thomas D, Exner E, Schmitt-Bormann B, Schaller T, Laage R, Schönborn-Kellenberger O, Arndt M, Haefeli WE, Krauss J First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteers. Clin Transl Sci. 2022 Oct;15(10):2366-2377


Scheldeman L, Wouters A, Dupont P, Christensen S, Boutitie F, Cheng B, Ebinger M, Endres M, Fiebach JB, Gerloff C, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Ringelstein EB, Chamorro A, Grond M, Laage R, Schneider A, Thomalla G, Thijs V, Lemmens R. Reversible Edema in the Penumbra Correlates with Severity of Hypoperfusion. Stroke. 2021 Jul;52(7):2338-2346. 


Campbell BCV, Ma H, Ringleb PA, Parsons MW, Churilov L, Bendszus M, and the EXTEND, ECASS-4, and EPITHET Investigators. Extending thrombolysis to 4·5-9 h and wake-up stroke using perfusion imaging: a systematic review and meta-analysis of individual patient data.

Lancet. 2019 Jul 13;394(10193):139-147. 


 Wouters A, Cheng B, Christensen S, Dupont P, Robben D, Norrving B, Laage R, Thijs VN, Albers GW, Thomalla G, Lemmens R.  Automated DWI analysis can identify patients within the thrombolysis time window of 4.5 hours. Neurology. 2018 May 1;90(18):e1570-e1577


 Wouters A, Dupont P, Norrving B, Laage R, Thomalla G, Albers GW, Thijs V, Lemmens R. Prediction of Stroke Onset Is Improved by Relative Fluid-Attenuated Inversion Recovery and Perfusion Imaging Compared to the Visual Diffusion-Weighted Imaging/Fluid-Attenuated Inversion Recovery Mismatch. Stroke.  2016 Oct;47(10):2559-64.



·  More Publications


GUIDED Development

Alte Eppelheimer Str. 23

69115 Heidelberg


Phone: +49 6221 65 34 650

Druckversion | Sitemap
© Guided Development